News
-
-
PRESS RELEASE
Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch
Jaguar Health's Napo Pharmaceuticals to showcase Gelclair, an FDA-approved oral mucositis prescription product, at ASTRO Annual Meeting. Gelclair offers pain relief and support for cancer patients -
-
-
-
PRESS RELEASE
Jaguar Health Appoints Industry Veteran to Head Sales for Company’s Commercialized Oncology and HIV Products Including October 2024 Launch of Gelclair for Cancer Supportive Care
Jaguar Health, Inc. appoints Susan Krizancic as National Sales Director for Napo Pharmaceuticals, preparing for FDA-approved Gelclair® oral mucositis product launch in October 2024 -
-
-
-
PRESS RELEASE
Jaguar Health Celebrates National Service Dog Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs
Jaguar Health's Canalevia-CA1 drug receives FDA conditional approval for chemotherapy-induced diarrhea treatment in dogs, making it the first approved treatment for this condition
